{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2"},{"groupId":"OG001","value":"56.6"},{"groupId":"OG002","value":"65.5"},{"groupId":"OG003","value":"70.9"},{"groupId":"OG004","value":"69.5"},{"groupId":"OG005","value":"71.0"}]}],"title":"EULAR Good Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1"},{"groupId":"OG001","value":"39.1"},{"groupId":"OG002","value":"29.8"},{"groupId":"OG003","value":"25.9"},{"groupId":"OG004","value":"26.8"},{"groupId":"OG005","value":"25.1"}]}],"title":"EULAR Moderate Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"514"},{"groupId":"OG001","value":"468"},{"groupId":"OG002","value":"429"},{"groupId":"OG003","value":"409"},{"groupId":"OG004","value":"380"},{"groupId":"OG005","value":"362"}],"units":"Participants"}],"description":"Participants were classified as responders based on a European League Against Rheumatism (EULAR) response of Good or Moderate. Comparing the DAS28 from one patient on two different time points, it is possible to define improvement or response. The EULAR response criteria take into consideration both the first score and the change in score in order to classify them as good response, moderate response or no response. The percentage of participants who were classified as responders was recorded, as posted below.","groups":[{"description":"Participants with scores at 24 weeks post-baseline.","id":"OG000","title":"Week 24"},{"description":"Participants with scores at 48 weeks post-baseline.","id":"OG001","title":"Week 48"},{"description":"Participants with scores at 108 weeks post-baseline.","id":"OG002","title":"Week 108"},{"description":"Participants with scores at 156 weeks post-baseline.","id":"OG003","title":"Week 156"},{"description":"Participants with scores at 204 weeks post-baseline.","id":"OG004","title":"Week 204"},{"description":"Participants with scores at 264 weeks post-baseline.","id":"OG005","title":"Week 264"}],"paramType":"NUMBER","populationDescription":"All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time.","reportingStatus":"POSTED","timeFrame":"through 264 Weeks","title":"Percentage of Participants Classified as Responders by EULAR Response Over Time, Through 264 Weeks","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}